Filing Details
- Accession Number:
- 0001209191-24-005060
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-22 16:31:10
- Reporting Period:
- 2024-03-20
- Accepted Time:
- 2024-03-22 16:31:10
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1658247 | Crinetics Pharmaceuticals Inc. | CRNX | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1397266 | K Matthew Fust | C/O Crinetics Pharmaceuticals, Inc. 6055 Lusk Boulevard San Diego CA 92121 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-03-20 | 12,500 | $23.24 | 31,036 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-03-20 | 12,500 | $43.57 | 18,536 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-03-20 | 12,500 | $23.23 | 31,036 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-03-20 | 12,500 | $43.57 | 18,536 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-03-20 | 17,500 | $20.23 | 36,036 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-03-20 | 17,500 | $43.58 | 18,536 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-03-20 | 17,500 | $18.29 | 36,036 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-03-20 | 17,500 | $45.50 | 18,536 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Acquisiton | 2024-03-20 | 12,500 | $0.00 | 12,500 | $23.24 |
| Common Stock | Stock Option (right to buy) | Acquisiton | 2024-03-20 | 12,500 | $0.00 | 12,500 | $23.23 |
| Common Stock | Stock Option (right to buy) | Acquisiton | 2024-03-20 | 17,500 | $0.00 | 17,500 | $20.23 |
| Common Stock | Stock Option (right to buy) | Acquisiton | 2024-03-20 | 17,500 | $0.00 | 17,500 | $18.29 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2029-06-20 | No | 4 | M | Direct | |
| 0 | 2030-06-18 | No | 4 | M | Direct | |
| 0 | 2031-06-21 | No | 4 | M | Direct | |
| 0 | 2032-06-16 | No | 4 | M | Direct |
Footnotes
- The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $43.57 per share. The range of sales prices on the transaction date was $42.70 to $44.23 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
- The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $43.58 per share. The range of sales prices on the transaction date was $42.70 to $44.23 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
- The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Billionaire Hedge Funds
